Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853782 | 0.84 | RIPK1 (0.51) | RIPK1OPRM1OPRL1SIGMAR1MEN1 | |
| SCHEMBL19853780 | 0.84 | MEN1 (0.46) | RIPK1OPRM1OPRL1SIGMAR1MEN1 | |
| SCHEMBL19839918 | 0.81 | GAA (0.49) | RIPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL19839346 | 0.80 | GAA (0.48) | RIPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL19853665 | 0.80 | GAA (0.48) | RIPK1OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL19853779 | 0.78 | GAA (0.51) | RIPK1OPRM1OPRL1SIGMAR1MEN1 | |
| SCHEMBL10199 | 0.78 | OPRM1 (0.44) | OPRM1OPRL1SIGMAR1MEN1KMT2A | |
| SCHEMBL10198 | 0.78 | OPRM1 (0.44) | OPRM1OPRL1SIGMAR1MEN1KMT2A | |
| SCHEMBL1588789 | 0.78 | OPRM1 (0.44) | OPRM1OPRL1SIGMAR1MEN1KMT2A | |
| SCHEMBL19853781 | 0.77 | MMP1 (0.50) | RIPK1OPRM1OPRL1SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490974-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2023-12-06 | — | — | EP | disclosed |
| CN-109906218-B | Spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-11512051-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-3490974-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| WO-2018026763-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026763-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | RIPK1 947/4885OPRM1 35/4885OPRL1 27/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | RIPK1 947/4885OPRM1 35/4885OPRL1 27/4885 |
| US-11512051-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | RIPK1 947/4885OPRM1 35/4885OPRL1 27/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | RIPK1 1861/4885OPRM1 353/4885OPRL1 55/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | RIPK1 947/4885OPRM1 35/4885OPRL1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.